Associated factors regarding systemic anticancer therapy use prior to death among patients with metastatic…

Cohort studyLung cancer (Amsterdam, Netherlands)· Jul 2026

Associated factors regarding systemic anticancer therapy use prior to death among patients with metastatic non-small cell lung cancer: A multicentre retrospective cohort study.

Kiki Mokkenstorm, Salomé van Beusekom, Camille Breukhoven … Santeon VBHC lung cancer group

Palliative & End-of-LifeCohort studyClinical practiceQ1IF 4.9

Prior hospitalization was linked to anticancer therapy in the final six weeks of life.

Associated factors regarding systemic anticancer therapy use prior to death among patients with metastatic non-small cell lung cancer: A multicentre retrospective cohort study.

Kiki Mokkenstorm … Santeon VBHC lung cancer group

Lung cancer (Amsterdam, Netherlands) · Jul 2026

Background

Systemic anticancer therapy (systemic anticancer therapy) near the end of life among patients with metastatic non-small cell lung cancer (non-small cell lung cancer) is considered a population-level quality indicator of potentially inappropriate end-of-life care.

Purpose

We investigated factors associated with systemic anticancer therapy in the final 6 weeks of life among patients diagnosed with metastatic non-small cell lung cancer to optimise end-of-life care.

Methods

A multicentre retrospective cohort study was conducted among patients with metastatic non-small cell lung cancer across 7 hospitals in the Dutch Santeon network.

Results

prior hospital stays raised the odds of late chemo or immunotherapy near death

OR 1.69 (95% CI 0.86 to 3.31)

null 1

0.86

3.31

CI crosses the null - not significant

More results

Among 365 included patients, 37 % received systemic anticancer therapy in the last 6 weeks of life.

Notably, these patients were significantly more likely to die in a hospital (44.1 % vs 9.6 %), to visit the emergency department (77.9 % vs 32.8 %) or to be hospitalised in the last 6 weeks of life (80.1 % vs 37.1 %).

“

Conclusion

This study highlights the importance of better understanding potentially inappropriate care near the end of life among patients with metastatic non-small cell lung cancer, specifically when focusing on previous hospitalisations or emergency department visits.

Associated factors regarding systemic anticancer therapy use prior to death among patients with metastatic non-small cell lung cancer: A multicentre retrospective cohort study.

Associated factors regarding systemic anticancer therapy use prior to death among patients with metastatic non-small cell lung cancer: A multicentre retrospective cohort study.

Related papers